Real-world efficacy and safety of naltrexone-bupropion therapy in Chinese patients with obesity: A single-centre experience.

IF 3.7 3区医学 Q2 Medicine

Endocrine Pub Date : 2025-02-01 Epub Date: 2024-10-05 DOI:10.1007/s12020-024-04029-2

David Tak Wai Lui, Kimberly Hang Tsoi, Carol Ho Yi Fong, Nancy Su Jiang, Wing Sun Chow, Michele Mae Ann Yuen

{"title":"Real-world efficacy and safety of naltrexone-bupropion therapy in Chinese patients with obesity: A single-centre experience.","authors":"David Tak Wai Lui, Kimberly Hang Tsoi, Carol Ho Yi Fong, Nancy Su Jiang, Wing Sun Chow, Michele Mae Ann Yuen","doi":"10.1007/s12020-024-04029-2","DOIUrl":null,"url":null,"abstract":"Purpose: Naltrexone-bupropion (Contrave®) has shown efficacy and safety in large randomised controlled trials, predominantly comprising Caucasians. Data are limited in Asian populations. We carried out a retrospective matched cohort study of Chinese patients with obesity to evaluate the efficacy and safety of naltrexone-bupropion in real-world clinical practice.Methods: We performed a retrospective matched cohort study of Chinese patients with obesity managed in the Obesity Clinic of Queen Mary Hospital in Hong Kong between 1 January 2016 and 31 December 2020. Electronic health records of patients treated with naltrexone-bupropion were retrieved for body weight and height, obesity-related metabolic parameters, and adverse events over a 12-month period. Age- and sex-matched controls from the Obesity Clinic who were only on self-directed lifestyle management were identified for comparison of weight changes. General linear models were used to analyse the change in body weight over 12 months.Results: Thirty-seven patients treated with naltrexone-bupropion were included (mean age 42.2 ± 8.4 years, 54.1% men, baseline body mass index 37.3 ± 4.6 kg/m2), and 37 age- and sex-matched controls were included. Among the 37 naltrexone-bupropion-treated patients, the mean weight loss was 9.2 ± 5.2% at 6 months and 9.7 ± 8.1% at 12 months, which were significantly more than in controls (p < 0.001). Improvements in the obesity-related parameters were observed in association with weight loss over 12 months. Ten patients (27.0%) discontinued naltrexone-bupropion due to side effects, mainly neurological and gastrointestinal manifestations, within the first 12 months.Conclusion: We demonstrated real-world efficacy and safety of naltrexone-bupropion among Chinese patients with obesity.","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"522-529"},"PeriodicalIF":3.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11811244/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12020-024-04029-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Naltrexone-bupropion (Contrave®) has shown efficacy and safety in large randomised controlled trials, predominantly comprising Caucasians. Data are limited in Asian populations. We carried out a retrospective matched cohort study of Chinese patients with obesity to evaluate the efficacy and safety of naltrexone-bupropion in real-world clinical practice.

Methods: We performed a retrospective matched cohort study of Chinese patients with obesity managed in the Obesity Clinic of Queen Mary Hospital in Hong Kong between 1 January 2016 and 31 December 2020. Electronic health records of patients treated with naltrexone-bupropion were retrieved for body weight and height, obesity-related metabolic parameters, and adverse events over a 12-month period. Age- and sex-matched controls from the Obesity Clinic who were only on self-directed lifestyle management were identified for comparison of weight changes. General linear models were used to analyse the change in body weight over 12 months.

Results: Thirty-seven patients treated with naltrexone-bupropion were included (mean age 42.2 ± 8.4 years, 54.1% men, baseline body mass index 37.3 ± 4.6 kg/m²), and 37 age- and sex-matched controls were included. Among the 37 naltrexone-bupropion-treated patients, the mean weight loss was 9.2 ± 5.2% at 6 months and 9.7 ± 8.1% at 12 months, which were significantly more than in controls (p < 0.001). Improvements in the obesity-related parameters were observed in association with weight loss over 12 months. Ten patients (27.0%) discontinued naltrexone-bupropion due to side effects, mainly neurological and gastrointestinal manifestations, within the first 12 months.

Conclusion: We demonstrated real-world efficacy and safety of naltrexone-bupropion among Chinese patients with obesity.

查看原文本刊更多论文

纳曲酮-安非他酮治疗中国肥胖症患者的实际疗效和安全性：单中心经验。

目的：纳曲酮-安非他明（Contrave®）在大型随机对照试验中显示出疗效和安全性，这些试验主要针对白种人。在亚洲人群中的数据有限。我们对中国肥胖症患者进行了一项回顾性匹配队列研究，以评估纳曲酮-安非他酮在实际临床实践中的疗效和安全性：我们对2016年1月1日至2020年12月31日期间在香港玛丽医院肥胖症诊所接受治疗的中国肥胖症患者进行了一项回顾性匹配队列研究。研究人员检索了接受纳曲酮-安非他酮治疗的患者的电子健康记录，以了解他们在12个月内的体重和身高、肥胖相关代谢指标以及不良事件。为了比较体重变化情况，研究人员还从肥胖症门诊中找出了年龄和性别相匹配、只接受自我生活方式管理的对照组。采用一般线性模型分析12个月内的体重变化：结果：共纳入 37 名接受纳曲酮-安非他酮治疗的患者（平均年龄为 42.2 ± 8.4 岁，54.1% 为男性，基线体重指数为 37.3 ± 4.6 kg/m2）和 37 名年龄和性别匹配的对照组。在接受纳曲酮-安非他酮治疗的 37 名患者中，6 个月和 12 个月的平均体重减轻率分别为 9.2 ± 5.2%和 9.7 ± 8.1%，明显高于对照组（P 结论：我们证明了纳曲酮-安非他酮治疗的实际疗效：我们证明了纳曲酮-安非他酮在中国肥胖症患者中的实际疗效和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Endocrine 医学-内分泌学与代谢

CiteScore

6.40

自引率

5.40%

发文量

期刊介绍： Well-established as a major journal in today’s rapidly advancing experimental and clinical research areas, Endocrine publishes original articles devoted to basic (including molecular, cellular and physiological studies), translational and clinical research in all the different fields of endocrinology and metabolism. Articles will be accepted based on peer-reviews, priority, and editorial decision. Invited reviews, mini-reviews and viewpoints on relevant pathophysiological and clinical topics, as well as Editorials on articles appearing in the Journal, are published. Unsolicited Editorials will be evaluated by the editorial team. Outcomes of scientific meetings, as well as guidelines and position statements, may be submitted. The Journal also considers special feature articles in the field of endocrine genetics and epigenetics, as well as articles devoted to novel methods and techniques in endocrinology. Endocrine covers controversial, clinical endocrine issues. Meta-analyses on endocrine and metabolic topics are also accepted. Descriptions of single clinical cases and/or small patients studies are not published unless of exceptional interest. However, reports of novel imaging studies and endocrine side effects in single patients may be considered. Research letters and letters to the editor related or unrelated to recently published articles can be submitted. Endocrine covers leading topics in endocrinology such as neuroendocrinology, pituitary and hypothalamic peptides, thyroid physiological and clinical aspects, bone and mineral metabolism and osteoporosis, obesity, lipid and energy metabolism and food intake control, insulin, Type 1 and Type 2 diabetes, hormones of male and female reproduction, adrenal diseases pediatric and geriatric endocrinology, endocrine hypertension and endocrine oncology.